Lotte Biologics Concentrates Entire Workforce in Songdo... Accelerates Commercial Production Preparations for Next Year 'Breaking'

Headquarters Functions Integrated from Jamsil and Songdo Offices
Plant 1 Undergoing C&Q, Full-Scale Commissioning Set for Second Half

Lotte Biologics has completed the relocation of all its executives and employees to the Incheon Songdo Bio Campus, accelerating preparations for commercial production in 2027.

Lotte Biologics announced on the 18th that it has finished relocating its employees, who had previously been spread across the Jamsil office, Songdo office, and temporary offices within the Songdo Bio Campus. With this move, the company has consolidated its headquarters functions and production infrastructure at the Songdo Bio Campus, enabling all organizational capabilities to be focused in one location.

A panoramic view of Lotte Biologics Incheon Songdo Bio Campus Plant 1. Lotte Biologics

The company expects faster decision-making during the commercial production preparation phase as major departments—including management, production, quality, engineering, and business development—are now working together in one space. This integration is expected to speed up processes such as customer support, technology transfer, process preparation, and quality review. The company also plans to establish a system that enables more agile responses to key issues arising directly at the production site.

Lotte Biologics aims to quickly reflect customer requirements at the production site and respond to manufacturing and quality issues in real time, thereby securing the high level of operational competitiveness demanded by global clients. Real-time sharing of status updates between the company’s Syracuse Bio Campus in the U.S. and the Songdo production facility is also expected to strengthen work collaboration.

Follow-up work to ensure the Songdo production facility is 'GMP Ready' is also expected to speed up. Currently, Plant 1 is undergoing qualification assessment (C&Q) for all equipment and utilities. In the second half of this year, the company is preparing for comprehensive commissioning and verification of the manufacturing and quality systems, aiming to establish a GMP production system that meets global regulatory standards.

A Lotte Biologics official stated, “The move to Songdo is a significant milestone, focusing all of the company’s capabilities at the Songdo Bio Campus ahead of commercial production. We will organically connect the global production experience accumulated in Syracuse with Songdo’s cutting-edge production infrastructure to provide trusted CDMO (contract development and manufacturing organization) services to our clients, and we are committed to flawlessly completing the remaining procedures.”

This content was produced with the assistance of AI translation services.